Tonix Launches Its New Fibromyalgia Drug in US
Wedoany.com Report-Dec.1, Tonix Pharmaceuticals has commercially launched Tonmya (cyclobenzaprine HC...
Novo Nordisk Seeks Extra-Fast Nod From FDA for Higher Dose of Wegovy
Wedoany.com Report-Dec.1, Novo Nordisk has submitted a regulatory filing to the U.S. Food and Drug A...
Zydus Life Gets US FDA Nod for Generic Version of Antidiabetic Combination Drug Glyxambi
Wedoany.com Report-Dec.1, Zydus Lifesciences has received tentative approval from the United States ...
Iraq to Open Largest Cancer Drug Factory in December
Wedoany.com Report-Nov. 30, Iraq is set to open the region’s largest cancer drug manufacturing facil...
EU Approves Sanofi and Regeneron’s Dupixent as First Targeted CSU Treatment in More Than a Decade
Wedoany.com Report-Nov. 29, The European Commission has approved Dupixent (dupilumab), developed by ...
Innovent Gets Ok for China’s First Home-Grown Il-23p19 Drug
Wedoany.com Report-Nov. 29, Innovent Biologics has received approval from China\'s National Medical ...
Over Half of European HIV Patients Diagnosed Late, ECDC Report Finds
Wedoany.com Report-Nov. 29, The European Centre for Disease Prevention and Control (ECDC) released i...
Celltrion Secures Health Canada Go-Ahead for Eylea Biosimilar
Wedoany.com Report-Nov. 29, Health Canada has granted regulatory approval to Celltrion\'s Eydenzelt ...
Novartis Korea Secures Reimbursement for Cosentyx in Hidradenitis Suppurativa
Wedoany.com Report-Nov. 28, Novartis Korea has announced that Cosentyx (secukinumab), its interleuki...
FDA Approves Treatment for Bladder Cancer
Wedoany.com Report-Nov. 28, The US Food and Drug Administration has approved two regimens combining ...
SK Bolsters Oncology Pipeline in Radiopharmaceutical Licensing Deal
Wedoany.com Report-Nov. 28, SK Biopharmaceuticals has expanded its oncology pipeline by in-licensing...
Valneva Trims R&D Footprint by Shutting French Facility
Wedoany.com Report-Nov. 28, Valneva has announced the closure of its 3,178 m² facility in Nantes, Fr...
CMS Sets 2027 Medicare Prices for Wegovy, Trelegy and 13 Other Drugs
Wedoany.com Report-Nov. 27, The Centers for Medicare & Medicaid Services (CMS) announced on Tues...
US FDA Extends Review of Ascendis Pharma’s Therapy for Children With Dwarfism
Wedoany.com Report-Nov. 27, The U.S. Food and Drug Administration has extended its review of Ascendi...
US Medicare Price Cuts Manageable for Most Drugmakers, Analysts Say
Wedoany.com Report-Nov. 27, The European Commission has approved Dupixent (dupilumab), developed by ...
Dupixent Gains Chronic Spontaneous Urticaria Indication in Europe
Wedoany.com Report-Nov. 27, The European Commission has approved Dupixent (dupilumab), developed by ...
Novo Nordisk’s Amycretin Cuts Body Weight, Blood Sugar in Phase 2 Diabetes Trial
Wedoany.com Report-Nov. 26, Novo Nordisk has announced positive mid-stage clinical results for its e...
Novartis Wins Approval to Use SMA Gene Therapy in Older Patients
Wedoany.com Report-Nov. 26, The U.S. Food and Drug Administration has approved Novartis’ new gene th...
Eli Lilly Becomes First Drugmaker to Hit $1 Trillion in Market Value
Wedoany.com Report-Nov. 26, Eli Lilly briefly became the world’s first pharmaceutical company to rea...
US Slashes 36% off Medicare Spending on 15 High-Priced Medicines
Wedoany.com Report-Nov. 26, The U.S. Medicare program announced on Tuesday that newly negotiated pri...
Novo Nordisk Alzheimer’s Drug Trials Fail in Blow to Weight-Loss Giant
Wedoany.com Report-Nov. 25, Novo Nordisk (NOVOb.CO) announced on Monday that two large Phase III tri...
Bayer Shares up More Than 8% on Revived Fortunes for Blood Thinner
Wedoany.com Report-Nov. 25, Bayer (BAYGn.DE) shares rose more than 8 percent on Monday after the com...
Gavi, Unicef Sign Deal to Cut Malaria Vaccine Price
Wedoany.com Report-Nov. 25, Gavi, the global vaccine alliance, and Unicef have secured an agreement ...
US FDA Approves Novartis’ Gene Therapy for Rare Muscle Disorder
Wedoany.com Report-Nov. 25, Novartis (NOVN.S) announced on Monday that the U.S. Food and Drug Admini...
